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Abstract Over the past 3 decades, fine needle aspiration
(FNA) has developed as the most accurate and cost-
effective initial method for guiding the clinical manage-
ment of patients with thyroid nodules. Thyroid FNA
specimens containing follicular-patterned lesions are the
most commonly encountered and include various forms of
benign thyroid nodules, follicular carcinomas, and the
follicular variant of papillary thyroid carcinoma. Based
primarily upon the cytoarchitectural pattern, FNA is used
as a screening test for follicular-patterned lesions to iden-
tify the majority of patients with benign nodules who can
be managed without surgical intervention. The terminology
and reporting of thyroid FNA results have been problem-
atic due to significant variation between laboratories, but
the recent multidisciplinary NCI Thyroid FNA State of the
Science Conference has provided a seven-tiered diagnostic
solution. A key element of this approach is the category
‘‘atypical cells of undetermined significance’’ (ACUS)
which is used for those aspirates which cannot be easily
classified as benign, suspicious, or malignant. Lesions in
this category represent approximately 3–6% of thyroid
FNAs and have a risk of malignancy intermediate between
the ‘‘benign’’ category and the ‘‘suspicious for a follicular
neoplasm’’ category. The recommended follow-up for an
ACUS diagnosis is clinical correlation and in most cases,
repeat FNA sampling.
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Introduction
In many pathology practices, thyroid FNAs comprise a
significant proportion of non-gynecologic cytology speci-
mens reflecting the fact that nodules of the thyroid gland are
very common. It is estimated that as many as 4–7% of the
adult population has a palpable thyroid enlargement, and up
to 10 times this number of individuals have subclinical
nodules [1–4]. The majority of these thyroid nodules are
benign with only a fraction representing malignant disease
which accounts for approximately 1.1% of all cancers
annually [5]. The large number of benign thyroid nodules
relative to the small number of malignant ones creates a
clinical dilemma—how to manage patients with a detect-
able thyroid enlargement that statistically is more likely to
be benign? Over the past three decades, FNA has developed
as the most accurate and cost-effective initial method for
evaluating thyroid nodules [6]. In experienced hands, the
diagnostic accuracy of thyroid FNA for technically satis-
factory specimens ranges from 80 to[95% [7].
FNA can be used as either a screening test for follicular
carcinoma, or as a diagnostic test for other thyroid carci-
nomas including papillary carcinoma, medullary
carcinoma, undifferentiated carcinoma, and lymphoma.
The follicular-patterned lesion is the most commonly
encountered type of thyroid FNA specimen, and it will be
the focus of this discussion. Follicular-patterned lesions
include benign thyroid nodules (adenomatous nodules,
hyperplastic nodules, follicular adenomas), follicular car-
cinomas, and the follicular variant of papillary thyroid
carcinoma. The application of thyroid FNA in the evalua-
tion of the various follicular-patterned lesions, including
key diagnostic pitfalls, and recent advances by the NCI
Thyroid FNA State of the Science Conference in the
reporting of these lesions will be reviewed.
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Discussion
FNA as a Screening Test for Follicular Carcinoma
The application of FNA to distinguish benign follicular
nodules from follicular carcinomas is problematic because
the criteria for distinguishing between them are based upon
histologic evidence of transcapsular or vascular invasion.
Since invasion cannot be assessed by FNA, the question
becomes ‘‘how can FNA be used to evaluate follicular
neoplasia.’’ The answer is that FNA is used as a screening
test for follicular carcinoma. The cytologic criteria used to
distinguish benign from suspicious thyroid lesions includes
the follicular group architecture, smear cellularity, amount
of colloid, and cytologic atypia [8]. By far, the most
important of these criteria is cytoarchitecture [9, 10]. Thus,
while a specific diagnosis may not be given, it is possible to
subcategorize these lesions into two groups: those which
are almost certainly benign, and those which are suspicious
for a follicular neoplasm and possibly malignant. This
subcategorization identifies a majority of patients with
benign lesions for whom surgical intervention can usually
be avoided.
Benign thyroid nodules are characterized microscopi-
cally by a macrofollicular pattern which features large flat
sheets of follicular cells with small dark round nuclei in a
honeycomb arrangement, usually in a background of
moderate to abundant colloid (Fig. 1). The flat sheets of
cells result from fragmentation of macrofollicles with
extrusion of colloid during the smear preparation. In con-
trast, thyroid aspirates composed of microfollicles (small
follicular groups of 6–12 follicular cells in a ring with or
without a small amount of central colloid), crowded tra-
beculae, or 3-D groups of overlapping follicular cells are a
feature of follicular carcinomas as well as some adenomas
(Fig. 2). These aspirates are diagnosed as ‘‘suspicious for a
follicular neoplasm,’’ and it is this group of patients for
whom thyroid lobectomy is generally considered
warranted.
By sorting follicular lesions into two groups based pri-
marily upon cytoarchitecture, FNA can identify a large
subset of nodules that are benign, and that do not require
surgery. This approach works because follicular carcino-
mas are rarely composed of predominantly normal-sized or
macrofollicles [8, 10]. The key to using this approach is to
focus upon the predominant cytoarchitectural pattern. A
common pitfall is to identify a minor population of mi-
crofollicles and ignore the overall pattern. In addition, it is
important to also evaluate the nuclear features of the cells
to avoid the pitfall of the follicular variant of papillary
thyroid carcinoma.
Unfortunately, while FNA as a screening test is highly
sensitive, it lacks specificity. Approximately 15–30% of
aspirates diagnosed as ‘‘suspicious for a follicular neo-
plasm’’ are actually carcinomas while the remaining 70–
85% of nodules are benign. [11–13] A wide variety of
immunohistochemical and molecular markers have been
studied in an attempt to distinguish between benign thyroid
nodules and follicular carcinomas in FNA samples; how-
ever, to date, none has been identified with both high
sensitivity and specificity. Until such marker is available,
FNA will remain a screening test rather than a diagnostic
test for follicular carcinomas.
The Follicular Variant of Papillary Thyroid Carcinoma
The follicular variant of papillary thyroid carcinoma is the
most common subtype of papillary thyroid carcinomas [5].
Fig. 1 Thyroid FNA demonstrating a macrofollicular group of cells
in a background of abundant watery colloid. These features are
typical of a benign thyroid nodule. (Papanicolaou stain)
Fig. 2 Thyroid FNA showing follicular cells in a predominantly
microfollicular arrangement. This cytoarchitectural pattern is charac-
teristic of a follicular neoplasm. (Papanicolaou stain)
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In FNA specimens, it can pose a diagnostic challenge due
to the abundance of microfollicles or monolayer tissue
fragments mimicking a follicular neoplasm. In fact, among
those FNAs diagnosed as ‘‘suspicious for a follicular neo-
plasm’’ that are malignant in histologic follow-up, over
30% are identified as the follicular variant of papillary
thyroid carcinoma [13, 14]. In contrast to the hyperchro-
matic chromatin seen in follicular neoplasms, the follicular
variant of papillary thyroid carcinoma exhibits pale, pow-
dery chromatin along with nuclear grooves and occasional
intranuclear pseudoinclusions (Fig. 3). The cells tend to be
round to oval and less pleomorphic than the conventional
type of papillary carcinoma. Variable amounts of dense
colloid are frequently seen in this variant, and multinu-
cleated giant cells may also be identified. Usually the
cytologic diagnosis of the follicular variant of papillary
carcinoma is not difficult, but in a subset of cases, the
nuclear features can be quite subtle resulting in misclassi-
fication of the lesion. Development of methods to detect
RET/PTC rearrangements or point mutations of the BRAF
gene in routine thyroid FNA samples may prove useful for
solving this problem [15].
Reporting of Thyroid FNAs
A major challenge in the application of FNA to the diagnosis
of thyroid lesions has been the inconsistent use of termi-
nology for reporting results of thyroid FNAs both within
laboratories and between different institutions. Not only has
this hindered the sharing of information between different
institutions, but it has created difficulties for clinicians
managing patients with thyroid disease. A major advance on
this front was made by the NCI Thyroid FNA State of the
Science Conference which convened on October 22–23,
2007 in Bethesda, Maryland. It addressed issues including
indications for thyroid FNA, training, techniques, reporting
terminology, ancillary testing, and management guidelines
[16, 17]. Based upon the findings, a Bethesda System-type
diagnostic framework for reporting thyroid FNA results was
proposed that consists of seven general diagnostic categories
(Table 1). Importantly, the terms used for reporting results
are associated with a risk of malignancy which will impact
recommendations for patient management [16].
Atypical Cells of Undetermined Significance (ACUS)
While most follicular-patterned lesions can be accurately
assessed using thyroid FNA, a small subset of lesions exhibit
cytologic features that are intermediate between benign and
neoplastic. This so-called ‘‘indeterminate’’ category has
been used in various ways by different laboratories. Some
have used this category for any aspirate with atypia, for
others the category has been used to mean ‘‘indeterminate for
malignancy’’ or ‘‘indeterminate for neoplasia.’’ In the pro-
posed Bethesda System for thyroid cytology, the ACUS or
indeterminate category is specifically designated for use
when the ‘cytologic and/or architectural atypia encountered
is of uncertain significance: it is of an insufficient degree to
qualify for any of the suspicious or malignant categories’
[18]. At the same time, the cytologic or architectural atypia is
more than would be acceptable within the ‘‘benign’’ cate-
gory. There are many different situations in which an ACUS
diagnosis would be used, but some of the most common
include the following: (1) a sparsely cellular aspirate with a
predominance of microfollicles, (2) cytologic atypia in the
setting of preparation artifact, (3) a mixed cytoarchitectural
pattern that includes nearly equal proportions of macrofol-
licles and microfollicles (Fig. 4), (4) focal atypia suggestive
of papillary carcinoma in an otherwise predominantly
benign-appearing sample (Fig. 5). Because of the potential
to overuse the ACUS category, it should be less than 7% of
all thyroid FNA interpretations [18]. For thyroid aspirates
diagnosed as ACUS, the recommended management is
clinicoradiologic correlation and in most cases, a repeat
Fig. 3 The follicular variant of papillary thyroid carcinoma is
characterized by cells with pale chromatin, somewhat enlarged oval
nuclei, and occasional longitudinal nuclear grooves in a background
of variable amounts of colloid. (Papanicoloau stain)
Table 1 Proposed 7-tiered Bethesda system for reporting of thyroid
cytologya
Diagnostic category Risk of malignancy (%)
Insufficient for diagnosis 1–4
Benign \1
Atypical cells of undetermined significance 5–10
Suspicious for a follicular neoplasm 15–30
Suspicious for a Hurthle cell neoplasm 15–45
Suspicious for malignancy 60–75
Malignant 97–99
a Modified from Cibas and Ali 2009
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FNA. The latter will often result in a more definitive
‘‘benign,’’ ‘‘suspicious,’’ or ‘‘malignant’’ designation; how-
ever, 20–25% of cases will result in a second ACUS
diagnosis [13, 18]. The risk of malignancy for an ACUS
diagnosis is difficult to assess because only a subset of ACUS
nodules will be surgically excised. However, it is estimated
that the overall risk of malignancy will be approximately
5–10% which is intermediate between the ‘‘benign’’ and
‘‘suspicious for a follicular neoplasm’’ categories [18].
Conclusions
Follicular-patterned thyroid lesions are a common and
sometimes challenging area of cytopathology. FNA has
developed as an effective means for evaluating these
lesions particularly when combined with the recently pro-
posed Bethesda System for reporting of thyroid FNAs. An
important advance in this regard is the use of diagnostic
categories with an associated risk of malignancy upon
which patient management decisions can be based.
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Fig. 4 This thyroid FNA demonstrates an indeterminate architectural
pattern and is placed into the category ‘‘Atypical cells of undeter-
mined significance (ACUS).’’ (Papanicolaou stain)
Fig. 5 This thyroid FNA contains occasional follicular cells with
enlarged, pale, grooved nuclei in an otherwise benign aspirate, and is
therefore diagnosed as ‘‘Atypical cells of undetermined significance
(ACUS).’’ (Papanicoloau stain)
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